Cantor Fitzgerald Weighs in on MiMedx Group FY2025 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for MiMedx Group in a research note issued to investors on Friday, May 2nd. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of $0.24 for the year, down from their prior estimate of $0.30. Cantor Fitzgerald has a "Overweight" rating and a $13.00 price objective on the stock. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $88.21 million during the quarter, compared to analysts' expectations of $86.32 million.

Separately, StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday.

MiMedx Group Stock Performance

Shares of NASDAQ:MDXG traded down $0.26 on Monday, hitting $7.16. 309,463 shares of the company were exchanged, compared to its average volume of 691,737. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The stock's 50 day moving average price is $7.30 and its 200 day moving average price is $8.10. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $10.14. The firm has a market capitalization of $1.06 billion, a P/E ratio of 13.02 and a beta of 1.85.

Insider Buying and Selling at MiMedx Group

In related news, CEO Joseph H. Capper acquired 200,000 shares of the stock in a transaction on Friday, May 2nd. The shares were acquired at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the transaction, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This trade represents a 60.69 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 144,018 shares of company stock worth $1,130,312. Company insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. IMG Wealth Management Inc. acquired a new stake in shares of MiMedx Group during the 4th quarter valued at about $28,000. Virtus Fund Advisers LLC purchased a new position in MiMedx Group during the fourth quarter worth approximately $35,000. Van ECK Associates Corp acquired a new stake in MiMedx Group in the fourth quarter valued at approximately $40,000. Tower Research Capital LLC TRC increased its position in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after buying an additional 2,837 shares in the last quarter. Finally, AlphaQuest LLC acquired a new position in shares of MiMedx Group during the 4th quarter worth approximately $88,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.